glp 1 for kidney disease GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1s lower BMI, preserve kidney
Description
The convergence of T2DM and CVD has led to the creation of drugs that can manage both glucose levels and cardiovascular risks, and Glucagon-like peptide-1 (GLP-1) receptor agonists are considered a significant advancement [3,4]
This popularity is transforming the pharmaceutical landscape and driving innovation in adjacent sectors such as medical devices, wellness tech, and digital health, which has led to an influx of investment by companies looking to capitalize on this rising trend
Ozempic is strictly for diabetes, while Wegovy, approved specifically for weight loss, complies with guidelines tailored to chronic weight management
Why Consider GLP-1 Therapy for Weight Loss
95% CI, 1.26-1.33), sleep disturbances (HR = 1.12
